Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teprasiran for AKI Prevention in Cardiac Surgery
NCT02610283Phase 2Completed
- Sponsor
- Quark Pharmaceuticals
- Start
- Dec 2015
- Primary completion
- Feb 2018
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 3
01
Overview
A Phase 2 trial of teprasiran in acute kidney injury (AKI), sponsored by Quark Pharmaceuticals. Started Dec 2015; status: completed.
02
Drugs
teprasiran
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT02610283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02610283.